Document is current
Any future updates will be listed below
-
Authors
Airagnes, Guillaume https://orcid.org/0000-0002-3494-5083
Lemogne, Cédric
Renuy, Adeline
Goldberg, Marcel
Hoertel, Nicolas
Roquelaure, Yves
Limosin, Frédéric
Zins, Marie
-
Funding
Funding for this research was provided by:
Agence Nationale de la Recherche (ANR-11-INBS-0002)
MSD, AstraZeneca and Lundbeck managed by INSERM-Transfert
Mission Interministérielle de Lutte Contre les Drogues et les Conduites Addictives
- License Information
-
More Information
Article History
Received: 18 December 2018
Accepted: 2 May 2019
First Online: 14 May 2019
Ethics approval and consent to participate
: The CONSTANCES cohort has obtained the authorization of the National Data Protection Authority (Commission Nationale de l’Informatique et des Libertés, no.910486) and was approved by the Institutional Review Board of the National Institute for Medical Research – INSERM (no. 01–011). Written informed consent was received from all of the subjects in the CONSTANCES cohort.
: Not applicable
: Guillaume Airagnes has received speaker and consulting fees from Lundbeck and Pfizer. Cédric Lemogne has received speaker and consulting fees from Daiichi- Sankyo, Janssen, Lundbeck, Otsuka Pharmaceuticals and Servier. Frédéric Limosin has received speaker and consulting fees from Astra Zeneca, Euthérapie-Servier, Janssen, Lundbeck, Otsuka Pharmaceuticals and Roche. Marcel Goldberg, Nicolas Hoertel, Yves Roquelaure and Marie Zins have nothing to declare.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
